Laden…
Methotrimeprazin (Levomepromazine) is a phenothiazine derivative with antipsychotic and sedative effects. It primarily acts by blocking dopamine-D2 and serotonin-5-HT2A receptors and additionally possesses antihistaminic and anticholinergic properties. The substance is used in psychiatry for the treatment of psychoses and for sedation; it is also applied in palliative medicine for pain and symptom control. Side effects may include sedation, orthostatic hypotension, and anticholinergic effects.
Class
Phenothiazine
Pharmacological context
Mechanism
5-HT2A receptor antagonist, D2 receptor antagonist
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Receptor Targets
Mechanism of Action
Methotrimeprazine (Levomepromazine) acts through the following pharmacological mechanisms:
Designations
IUPAC: Methotrimeprazine (Levomepromazine)
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der 5-HT2A-Rezeptor ist ein Serotonin-Rezeptor der Klasse Gq-gekoppelter GPCRs. Er ist der primäre molekulare Angriffspunkt klassischer Psychedelika und spielt eine Rolle bei Kognition und Wahrnehmung.
Der D2-Rezeptor ist ein Gi-gekoppelter Dopaminrezeptor mit hoher Dichte im Striatum. Er ist ein wichtiges Ziel für Antipsychotika und moduliert motorische Funktionen sowie Belohnungsverarbeitung.
Der H1-Rezeptor ist ein Gq/11-gekoppelter Histaminrezeptor, der an allergischen Reaktionen, Wachheit und Thermoregulation beteiligt ist. Antagonismus verursacht Sedierung und wird therapeutisch als Schlafhilfe und Antiallergikum genutzt.
Der M1-Muskarinrezeptor ist ein Gq/11-gekoppelter Acetylcholinrezeptor, der eine zentrale Rolle bei Kognition und Gedächtnis spielt. Antagonismus kann Verwirrtheit, Gedächtnisstörungen und anticholinerges Delir verursachen.
Synapedia Evidence
Effects & Pharmacology translation in progress
English prose is being expanded. The German version currently has more detail.
Reported range 25 mg
Total duration 12–24 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 6.25 mg |
| Reported | 25 mg |
| Strong | 100 mg |
Oral
Onset
30–60 minutes
Peak
2–4 hours
Total duration
12–24 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Nebenwirkungen umfassen Sedierung, anticholinerge Effekte und extrapyramidale Symptome.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.